LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18

Rhea-AI Summary

LumiraDx (LMDX) announced that it will release its Q2 financial results on August 18, 2022. A conference call will follow at 8:00 AM ET to discuss the results and business highlights. LumiraDx specializes in point of care diagnostics, offering over 30 tests across various health conditions, including infectious diseases and diabetes. The company aims to transform community-based healthcare with diagnostic solutions utilized by numerous healthcare institutions worldwide. Investors can access a replay of the call on their website after the event.

Positive

• LumiraDx offers a robust portfolio of over 30 diagnostic tests.
• The company is positioned in the fast-growing point of care diagnostics market.
• Collaborations with governments and leading healthcare institutions enhance market penetration.

Negative

• None.

LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18^th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights.

	LumiraDx Second Quarter 2022 Financial Results Conference Call
Date:	Thursday, August 18, 2022
Time:	8:00 AM Eastern Time
Live Call/Webcast:	Register to join by phone here. https://investors.lumiradx.com/news-and-events/investor-calendar

A replay of the webcast will be available on the Investor's section of the company's website at investors.lumiradx.com shortly after the conclusion of the call. The webcast will be archived for one year.

About LumiraDx
LumiraDx (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, LumiraDx manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform. In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.
Further information on LumiraDx and the LumiraDx Platform is available at www.lumiradx.com 

Contact:
Colleen McMillen
Colleen.McMillen@lumiradx.com

FAQ

When will LumiraDx announce its Q2 financial results?

LumiraDx will announce its Q2 financial results on August 18, 2022.

What time is the LumiraDx conference call for financial results?

The LumiraDx conference call will take place at 8:00 AM Eastern Time on August 18, 2022.

Where can I find the LumiraDx Q2 financial results after the announcement?

The Q2 financial results replay will be available on the investor section of LumiraDx's website shortly after the call.

What is the focus of LumiraDx's testing solutions?

LumiraDx focuses on point of care diagnostics for infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders.